Podofilox

CHEMBL61 Phase 4 已批准 Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
414.4 g/mol
LogP
2.0
Phase
4

Podofilox (podophyllotoxin) is an antimitotic agent derived from the mayapple plant that inhibits microtubule assembly by binding to tubulin, thereby arresting cell division at metaphase and inducing apoptosis in rapidly dividing cells. It is used topically for the treatment of external genital and perianal warts (condylomata acuminata) caused by human papillomavirus.

分子量

414.4000 g/mol

LogP

2.00

TPSA

92.70 Ų

Lipinski 五规则

符合

治疗领域

作用机制

Applied directly to the skin or mucous membranes, where it exerts its therapeutic effect locally at the site of application with minimal systemic absorption.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

机制

Applied directly to the skin or mucous membranes, where it exerts its therapeutic effect locally at the site of application with minimal systemic absorption.

二维结构

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

COc1cc([C@@H]2c3cc4c(cc3[C@H](O)[C@H]3COC(=O)[C@H]23)OCO4)cc(OC)c1OC

InChI

InChI=1S/C22H22O8/c1-25-16-4-10(5-17(26-2)21(16)27-3)18-11-6-14-15(30-9-29-14)7-12(11)20(23)13-8-28-22(24)19(13)18/h4-7,13,18-20,23H,8-9H2,1-3H3/t13-,18+,19-,20-/m0/s1

Molecular Formula

C22H22O8

HBD / HBA

1 / 8

可旋转键数

4

重原子数

30

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

常见问题

Podofilox (podophyllotoxin) is an antimitotic agent derived from the mayapple plant that inhibits microtubule assembly by binding to tubulin, thereby arresting cell division at metaphase and inducing apoptosis in rapidly dividing cells. It is used topically for the treatment of external genital and perianal warts (condylomata acuminata) caused by human papillomavirus.

Applied directly to the skin or mucous membranes, where it exerts its therapeutic effect locally at the site of application with minimal systemic absorption.

Yes, Podofilox is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL61. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 10607. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

医疗免责声明

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.